Last reviewed · How we verify
Ticagrelor-Reference product
At a glance
| Generic name | Ticagrelor-Reference product |
|---|---|
| Sponsor | Bio-innova Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (PHASE1)
- 1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials (NA)
- Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg (PHASE1)
- 1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon (NA)
- Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition (PHASE1)
- GLOBAL LEADERS Adjudication Sub-Study
- PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor (PHASE4)
- Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor-Reference product CI brief — competitive landscape report
- Ticagrelor-Reference product updates RSS · CI watch RSS
- Bio-innova Co., Ltd portfolio CI